Open Access

Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice

  • Authors:
    • Jian Liu
    • Haoyue Huang
    • Sheng Shi
    • Xu Wang
    • Yunsheng Yu
    • Yanqiu Hu
    • Jiacheng Sun
    • Chuanlu Ren
    • Junjie Yang
    • Zhenya Shen
  • View Affiliations

  • Published online on: September 4, 2018     https://doi.org/10.3892/etm.2018.6694
  • Pages: 3785-3792
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Apolipoprotein M (apoM) is a recently identified human apolipoprotein that is associated with the formation of high‑density lipoprotein (HDL). Studies have demonstrated that statins may affect the expression of apoM; however, the regulatory effects of statins on apoM are controversial. Furthermore, the underlying mechanisms by which statins regulate apoM remain unclear. In the present study, in vivo and in vitro models were used to investigate whether the anti‑atherosclerotic effects of statins are associated with its apoM‑regulating effects and the underlying mechanism. Hyperlipidemia was induced by in apolipoprotein E‑deficient mice by providing a high‑fat diet. Atorvastatin was administered to hyperlipidemic mice and HepG2 cells to investigate its effect on apoM expression. The liver X receptor α (LXRα) agonist T0901317 was also administered together with atorvastatin to hyperlipidemic mice and HepG2 cells. The results revealed that atorvastatin increased apoM expression, which was accompanied with decreased expression of LXRα in the liver of hyperlipidemic apolipoprotein E‑deficient mice and HepG2 cells. Additionally, apoM upregulation was inhibited following treatment with T0901317. In summary, atorvastatin exhibited anti‑atherosclerotic effects by upregulating apoM expression in hyperlipidemic mice, which may be mediated by the inhibition of LXRα.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 16 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu J, Huang H, Shi S, Wang X, Yu Y, Hu Y, Sun J, Ren C, Yang J, Shen Z, Shen Z, et al: Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice. Exp Ther Med 16: 3785-3792, 2018.
APA
Liu, J., Huang, H., Shi, S., Wang, X., Yu, Y., Hu, Y. ... Shen, Z. (2018). Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice. Experimental and Therapeutic Medicine, 16, 3785-3792. https://doi.org/10.3892/etm.2018.6694
MLA
Liu, J., Huang, H., Shi, S., Wang, X., Yu, Y., Hu, Y., Sun, J., Ren, C., Yang, J., Shen, Z."Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice". Experimental and Therapeutic Medicine 16.5 (2018): 3785-3792.
Chicago
Liu, J., Huang, H., Shi, S., Wang, X., Yu, Y., Hu, Y., Sun, J., Ren, C., Yang, J., Shen, Z."Atorvastatin upregulates apolipoprotein M expression via attenuating LXRα expression in hyperlipidemic apoE‑deficient mice". Experimental and Therapeutic Medicine 16, no. 5 (2018): 3785-3792. https://doi.org/10.3892/etm.2018.6694